CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

CSL Limited

Revenue

Price Targets

# of Analysts

Consensus Recommendation

EBITDA

EBIT

Free Cash Flow

FFO / Share

AFFO / Share

NAV / Share

Book Value / Share

CapEx

Estimates	Jun '24 (A)	Jun '25 (A)	Jun '26 (E)
Mean	$4,888.45	$5,269.14	$5,511.13
Median	$4,866.64	$5,223.92	$5,504.50
Actual	$4,750.00	$5,151.00	—
High	$5,053.49	$5,536.78	$5,941.60
Low	$4,724.00	$5,096.00	$4,903.00
Standard Deviation	$91.76	$129.15	$226.34
# of Estimates	15	17	16